PLx Pharma (FRA:1D5A) Additional Paid-In Capital : €191.47 Mil(As of Sep. 2022)

View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Additional Paid-In Capital?

PLx Pharma's quarterly additional paid-in capital increased from Mar. 2022 (€167.98 Mil) to Jun. 2022 (€177.26 Mil) and increased from Jun. 2022 (€177.26 Mil) to Sep. 2022 (€191.47 Mil).

PLx Pharma's annual additional paid-in capital increased from Dec. 2019 (€67.35 Mil) to Dec. 2020 (€74.97 Mil) and increased from Dec. 2020 (€74.97 Mil) to Dec. 2021 (€162.76 Mil).

PLx Pharma Additional Paid-In Capital Historical Data

The historical data trend for PLx Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PLx Pharma Additional Paid-In Capital Chart

PLx Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Additional Paid-In Capital

Get a 7-Day Free Trial

60.79

64.05

67.35

74.97

162.76

PLx Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Additional Paid-In Capital	Get a 7-Day Free Trial															155.30	162.76	167.98	177.26	191.47

PLx Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

PLx Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of PLx Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

PLx Pharma (FRA:1D5A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Inc (FRA:1D5A) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 The Green, Suite 11895, Dover, DE, USA, 19901

Website

https://www.plxpharma.com

PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.

PLx Pharma (FRA:1D5A) Headlines

No Headlines